Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults

• Published in: NEJM evidence Vol. 3; no. 3; p. EVIDoa2300290
• Main Authors: Morino, Eriko, Mine, Sohtaro, Tomita, Noriko, Uemura, Yukari, Shimizu, Yosuke, Saito, Sho, Suzuki, Tetsuya, Okumura, Nobumasa, Iwasaki, Haruka, Terada, Junko, Ainai, Akira, Sakai, Yusuke, Park, Eunsil, Seki, Sayuri, Akazawa, Daisuke, Shimojima, Masayuki, Shiwa-Sudo, Nozomi, Virhuez-Mendoza, Milagros, Miyauchi, Kosuke, Moriyama, Saya, Iwata-Yoshikawa, Naoko, Harada, Michiko, Harada, Shigeyoshi, Hishiki, Takayuki, Kotaki, Ryutaro, Matsumura, Takayuki, Miyamoto, Sho, Kanno, Takayuki, Isogawa, Masanori, Watashi, Koichi, Nagata, Noriyo, Ebihara, Hideki, Takahashi, Yoshimasa, Maeda, Ken, Matano, Tetsuro, Wakita, Takaji, Suzuki, Tadaki, Sugiura, Wataru, Ohmagari, Norio, Ujiie, Mugen
• Format: Journal Article
• Language: English
• Published: United States 27.02.2024
• Subjects: Adult; Antibodies, Neutralizing; Antigens, Viral; Humans; Mpox (monkeypox); Smallpox Vaccine; Vaccines

BACKGROUND: Vaccination against mpox (formerly known as monkeypox), an infectious disease caused by the monkeypox virus (MPXV), is needed to prevent outbreaks and consequent public health concerns. The LC16m8 vaccine, a dried cell-cultured proliferative live attenuated vaccinia virus–based vaccine,...